According to the latest report by IMARC Group, titled “Migraine Drugs Market Share: Global Industry Trends, Growth, Opportunity and Forecast 2022-2027”, The global migraine drugs market size reached US$ 3.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 5.4 Billion by 2027, exhibiting a growth rate (CAGR) of 5.72% during 2022-2027. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the market in any form.

Migraine represents the neurological condition that causes unilateral or throbbing pain in the side of the head, forehead, and around the eyes. It is usually accompanied by autonomic symptoms, such as vomiting, nausea, photophobia, phonophobia, etc. Migraine is diagnosed by examining the medical history and symptoms of the patient and performing magnetic resonance imaging (MRI), blood tests, computerized tomography (CT) scans, etc. Presently, prescribed injections and over-the-counter (OTC) medicines are widely utilized to minimize the frequency as well as the severity of migraine attacks. They are either taken regularly or during exacerbations of chronic pain.

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the global industry behaviours of the consumers globally. Our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

Global Migraine Drugs Market Trends:

The escalating demand for precision medicines is primarily driving the migraine drugs market. Additionally, the rising healthcare expenditure capacities of individuals and extensive improvement in reimbursement policies for migraine medications are further catalyzing the market growth. Besides this, various types of migraine drugs, including ergot alkaloids, triptans, NSAIDs, acetylcholine inhibitors/ neurotoxins, ditans, CGRP mAbs, etc., are commonly available via hospital-based pharmacies, which is acting as another significant growth-inducing factor. Moreover, the development of product variants with novel mechanisms of action or new therapeutic targets and the inflating need for electrical nerve stimulating devices to treat migraine are also positively influencing the global market. In line with this, the introduction of calcitonin gene-related peptide (CGRP) monoclonal antibodies that have higher clinical efficacy is anticipated to fuel the migraine drugs market over the forecasted period.

Request Free Sample Report: https://www.imarcgroup.com/migraine-drugs-market/requestsample

Global Migraine Drugs Market  2022-2027 Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Abbott Laboratories, Allergan Plc (Abbvie Inc.), Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA and Teva Pharmaceutical Industries Limited.

The report has segmented the market on the basis on region,  treatment type, drug type, route of administration and distribution channel.

Breakup by Treatment Type:

Abortive Treatment
Preventive Treatment

Breakup by Drug Type:

Triptans
Ergot Alkaloids
NSAIDs
Acetylcholine Inhibitors/ Neurotoxins
Ditans
CGRP mAbs
Others

Breakup by Route of Administration:

Oral
Injectable
Others

Breakup by Distribution Channel:

Hospital-Based Pharmacies
Retail Pharmacies
Others
Others

Breakup by Region:

North America: (United States, Canada)
Asia Pacific: (China, Japan,India, South Korea, Australia, Indonesia, Others)
Europe: (Germany, France,United Kingdom, Italy, Spain, Russia, Others)
Latin America: (Brazil, Mexico, Others)
Middle East and Africa

Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/migraine-drugs-market

If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.

Key highlights of the report:

Market Performance (2016-2021)
Market Outlook (2022- 2027)
Porter’s Five Forces Analysis
Market Drivers and Success Factors
SWOT Analysis
Value Chain
Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

Company Name: IMARC Group
Email: sales@imarcgroup.com
Toll Free Number: USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 30 N Gould St, Ste R
Sheridan, WY 82801, USA
Website: https://www.imarcgroup.com/
Linkedin: https://www.linkedin.com/company/imarc-group